CordenPharma Announcements at DCAT Week '16 > Dr. Roberto Margarita

Apr 07, 2016
During the DCAT Member Forum on Monday, March 14, 2016 of DCAT Week '16 at the Waldorf Astoria in New York City, Dr. Roberto MargaritaDirector, Global Antibiotics, Highly Potent & Oncology Platforms, CPI, presented 4 CordenPharma announcements to the DCAT Community.

DCAT Week '16

During the DCAT Member Forum
on Monday, March 14, 2016
at the Waldorf Astoria
in New York City

Dr. Roberto Margarita
(photo shown here courtesy of DCAT),
Director, Global Antibiotics, Highly Potent &
Oncology Platforms, CPI,

Presented 4 CordenPharma
Announcements to the DCAT Community:




  1. New Development Suite for Oral Highly Potent & Oncology Oral Dosage >

    Expanded OncologyHighly Potent Platforms with new capabilities for Oral Dosage Development > CordenPharma Plankstadt (DE) > read press release here

  2. New Development Suite for Small-Scale Aseptic Sterile Line >

    Expanded Injectables Platform with new capabilities for Small-Scale Aseptic Sterile > CordenPharma Caponago (IT) > read press release here

  3. Fully-Integrated Cephalosporin Supply Chain

    Expanded Antibiotics Platform with Completed Vertical Integration of CDMO Capacity for Cefalosporins > Acquisition by ICIG of CordenBioChem Frankfurt as of April 1, 2016 >
    read press release here

  4. New / Additional Sterile Capacity for Oncology Liquid & Lyophilisation >

    Expanded Oncology & Highly Potent Platforms with Additional Sterile Capacity for Oncology Liquid & Lyofilisation > CordenPharma Latina (IT) > Due to open July 2016